Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
Day: July 8, 2025
Alignment Healthcare Wins Key Legal Victory: Arizona Medicare Advantage Plans Elevated to 4 Stars
Court ruling means 100% of Alignment’s members now enrolled in plans rated 4 stars or greaterORANGE, Calif., July 08, 2025 (GLOBE...
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR,...
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans...
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ:...
Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited...
Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science
Combined company will leverage services and technology platforms to offer a broad portfolio of integrated solutions to pharmaceutical and device...
Vaxart Announces Trading on OTCQX Best Market
SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage...
iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in...
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ:...
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900’s Potential as a Combination Partner with Leading Therapies
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that...
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the...
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients11...
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Substantial clinical need expected to facilitate rapid overall trial enrollmentHOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:...
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors...
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology...
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24...
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations...
Diagonal Therapeutics Appoints John Lee, M.D., Ph.D., as Chief Medical Officer
Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary...